Coherus BioSciences, Inc.

NASDAQ (USD): Coherus BioSciences, Inc. (CHRS)

Last Price

1.71

Today's Change

+0.34 (24.81%)

Day's Change

1.67 - 2.43

Trading Volume

114,257,418

Overview

Market Cap

197 Million

Shares Outstanding

115 Million

Avg Volume

2,979,107

Avg Price (50 Days)

0.93

Avg Price (200 Days)

1.62

PE Ratio

-19.00

EPS

-0.09

Earnings Announcement

27-Feb-2025

Previous Close

1.37

Open

2.04

Day's Range

1.67 - 2.43

Year Range

0.66 - 3.7

Trading Volume

114,257,418

Price Change Highlight

1 Day Change

24.82%

5 Day Change

33.59%

1 Month Change

155.22%

3 Month Change

30.53%

6 Month Change

-3.93%

Ytd Change

-45.54%

1 Year Change

-25.65%

3 Year Change

-90.30%

5 Year Change

-90.66%

10 Year Change

-87.94%

Max Change

-86.44%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment